Amgen Inc.

Genor Biopharma Co., Ltd.

Inventio Ag

Tsi Health Sciences, Inc.

Joe Zhou

Jun Wang

Jun Lin

Pavel V Bondarenko

Yuefeng Lu

Douglas Rehder

Qing Zhou

Shaoxiong Wang

Weihong Nian

Steve S Lee

Richard B Hynson

Margaret Ricci

Yuling Zhang

Thomas M Dillon

Himanshu S Gadgil

Douglas D Banks

Hongbin Yan

Andrew Goetze

Felix M Solamo

Jianyang Zhao

Jiuru Sun

Rulei Chen

Xinxing Ma

Shu Shi

A method for verifying the brake force of an electromagnetic elevator brake includes the steps of closing the brake, supplying electrical current to the brake up to a preset verification level and determining whether there has been any movement of the elevator car being braked.

Brake force verification of an elevator brake

The present invention provides an anthropogenic glucagon-like peptide-1 (GLP-1) recombinant protein molecule fused with an anthropogenic immunoglobulin subtype (IgG2) Fc section and a preparation method and purpose thereof. The fusion protein has the biological activity of GLP-1, and also has a significantly prolonged half-life in vivo. The fusion protein can be used to treat type II diabetes, obesity, and other diseases that are treated by decreasing serum glucose, suppressing gastrointestinal motility, and emptying or suppressing food intake.

Long-acting blood sugar decreasing fusion protein

The invention provides methods for treating cell culture media for use in a bioreactor using ultraviolet C (UVC) light and filtration.

Methods of treating cell culture media for use in a bioreactor

The disclosure provides a novel anti-angiogenesis fusion protein. The present invention combines a chimeric vascular endothelial cell growth factor (VEGF) receptor or a fragment thereof with a multimerizing component, which have a superior binding capacity with human VEGF and placental growth factor (PIGF). The fusion protein has improved stability, prolonged half-life and the ability to form multivalent interactions with VEGF, and can be used for anti-angiogenesis, treating VEGF related diseases and inhibiting tumor growth.

Anti-angiogenesis fusion proteins

The present invention is generally directed to methods of producing an increase in the enrichment or recovery of preferred forms of IgG proteins. More particularly, the invention relates to subjecting preparations of such recombinant IgG proteins with a reduction/oxidation coupling reagent and optionally a chaotropic agent.

Methods for refolding of recombinant antibodies

The present invention is directed to compositions having an effective amount of Adenosine Triphosphate ('ATP') sufficient to effect intracellular and extracellular concentrations of ATP in a mammal to improve anaerobic exercise capacity by increasing muscle size and/or strength and methods for using the same. Preferably, a gastric acid secretion inhibitory coating is applied to the effective amount of ATP in a manner that protects the ATP from degradation by gastric juices. ATP compositions of the present invention may be administered in nutraceutical or functional food dosage forms, including oral and non-oral delivery forms. In addition, the effective amount of ATP maybe combined with amino acids, botanicals, functional foods, herbals, nucleotides, nutraceuticals, nutrients, pharmaceuticals, proteins, and/or vitamins in an effort to enhance the targeted activity of the composition.

Method for increasing muscle mass and strength through administration of adenosine triphosphate

Growing community of inventors

Shanghai, China

Joe Zhou